Brentuximab vedotin is an effective therapy for CD30+ mycosis fungoides and cutaneous anaplastic large‐cell lymphoma: what is the cost?

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2133|177|6|1474-1475

ISSN： 0007-0963

Source： BRITISH JOURNAL OF DERMATOLOGY, Vol.177, Iss.6, 2017-12, pp. : 1474-1475

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Assessment of diagnostic criteria between primary cutaneous anaplastic large‐cell lymphoma and CD30‐rich transformed mycosis fungoides; a study of 66 cases

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 6, 2015-06 ,pp. : 1547-1554

John Wiley & Sons Inc

Access to resources Recommend Favorite

Rapid response of nodular CD30‐positive mycosis fungoides to brentuximab vedotin

By  

BRITISH JOURNAL OF HAEMATOLOGY, Vol. 168, Iss. 5, 2015-03 ,pp. : 617-617

John Wiley & Sons Inc

Access to resources Recommend Favorite

A Case of Mycosis Fungoides after CD30 Positive Anaplastic Large Cell Lymphoma

By  

THE JOURNAL OF DERMATOLOGY, Vol. 27, Iss. 7, 2000-07 ,pp. : 458-461

John Wiley & Sons Inc

Access to resources Recommend Favorite

CD30‐rich transformed mycosis fungoides or anaplastic large cell lymphoma? How to get it right

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 172, Iss. 6, 2015-06 ,pp. : 1478-1479

John Wiley & Sons Inc

Access to resources Recommend Favorite

The optimal regimen of brentuximab vedotin for CD30+ cutaneous lymphoma: are we there yet?

By  

BRITISH JOURNAL OF DERMATOLOGY, Vol. 178, Iss. 2, 2018-02 ,pp. : 571-571

John Wiley & Sons Inc

Access to resources Recommend Favorite